UNIGE document Scientific Article
previous document  unige:27947  next document
add to browser collection

Targeting Olfactomedin-like 3 Inhibits Tumor Growth by Impairing Angiogenesis and Pericyte Coverage

Published in Molecular cancer therapeutics. 2012, vol. 11, no. 12, p. 2588-99
Abstract Anti-angiogenic drugs have been used as anti-cancer agents to target tumor endothelial cells or pericytes. Due to limited efficacy of the current mono-therapies, there is a strong demand for dual targeting of endothelial cells and pericytes. Here, we identify Olfactomedin-like 3 (Olfml3) as a novel pro-angiogenic cue within the tumor microenvironment. Tumor-derived Olfml3 is produced by both tumor endothelial cells and accompanying pericytes and deposited in the peri-vascular compartment. Blockade of Olfml3 by anti-Olfml3 antibodies is highly effective in reducing tumor vascularization, pericyte coverage and tumor growth. In vitro, Olfml3 targeting is sufficient to inhibit endothelioma cell migration and sprouting. Olfml3 alone or through binding to BMP4 enhances the canonical SMAD1/5/8 signaling pathway required for BMP4-induced angiogenesis. Therefore, Olfml3 blockade provides a novel strategy to control tumor growth by targeting two distinct cell types within the tumor microenvironment using a single molecule.
PMID: 23002094
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
Research group Bochaton-Piallat Marie-Luce (pathologie et immunologie) (646)
(ISO format)
MILJKOVIC-LICINA, Marijana et al. Targeting Olfactomedin-like 3 Inhibits Tumor Growth by Impairing Angiogenesis and Pericyte Coverage. In: Molecular cancer therapeutics, 2012, vol. 11, n° 12, p. 2588-99. doi: 10.1158/1535-7163.MCT-12-0245 https://archive-ouverte.unige.ch/unige:27947

484 hits

0 download


Deposited on : 2013-05-21

Export document
Format :
Citation style :